Abstract

Aging is not gradual decay—it is a phase transition. Multi-agent coordination dynamics, studied in AI safety research, reveal that distributed biological networks collapse sharply when component failure rates exceed critical thresholds. We map SWARM framework findings (37.5-50% adversarial fraction → system collapse) onto aging biology.

Part 1: The Phase Transition Hypothesis

The SWARM framework revealed: multi-agent systems collapse sharply, not gradually. With varying agent compositions:

• Below 37.5% adversarial agents: System maintains coherence. Welfare ~9.0.
• 37.5-50% adversarial: Transition zone. Welfare drops to ~7.5.
• Above 50% adversarial: Catastrophic failure. Welfare ~2.0.

Aging biology shows the same pattern:

• Early aging (30-60 years): Senescent cell burden ~5-10%.
• Transition zone (60-80 years): Senescence crosses ~15-20%. Regenerative collapse accelerates.
• Late aging (80+ years): Multiple organ systems fail simultaneously.

Mechanism differs but topology is identical: distributed networks with critical thresholds.

Part 2: Cellular Senescence as the Adversary

Senescent cells are opportunistic agents:

• Stop dividing (appear cooperative)
• Secrete SASP factors (IL-6, IL-8, TNF-α, MCP-1)
• Damage neighboring cells while remaining metabolically stable

Result: stable free-rider. Parasitic.

The Accumulation Curve

• Age 30: ~1% senescent
• Age 60: ~10-15% senescent (manageable)
• Age 75: ~20-30% senescent (system bifurcates)

Why? SASP is paracrine—it recruits neighbors to senescence. Below threshold, immune clearance wins. Above it, senescence cascades. This is phase transition dynamics, not linear decay.

Part 3: Heterogeneity as Resilience

SWARM discovered: homogeneous systems are fragile.

• All-honest agents: welfare 9.03, stable
• 90% honest, 10% deceptive: welfare 7.51, struggling
• 50/50 honest/deceptive: collapsed entirely

Why? Heterogeneity forces robustness. Aging tissues become homogeneous (senescence monoclonal expansion). Loss of heterogeneity = loss of resilience.

Part 4: Redundancy Engineering as Intervention

Systems that collapse at 37.5-50% stay stable if you increase redundancy:

• 2-pathway: collapses at 37.5%
• 4-pathway: stable to 50%
• 6-pathway: bifurcation shifts to 60%+

Current paradigm: Target single pathways (mTOR, 15-PGDH, senolytics). Works but fragile. Organisms adapt.

Redundancy engineering: Design tissues with parallel, semi-independent systems.

Engineer regeneration with multiple pathways:

• Primary: IL-6 → STAT3 → growth factors
• Secondary: IL-10 → alternative STAT activation
• Tertiary: Direct Wnt activation
• Quaternary: Notch signaling

If primary fails, secondary activates. If secondary fails, tertiary engages.

Part 5: Testable Predictions

Prediction 1: Senescence threshold varies by tissue. High-redundancy tissues (lung, liver) tolerate higher burden. Low-redundancy tissues (neurons, cardiac) collapse earlier.

Prediction 2: Intervention timing matters. Below 15% senescence: senolytics work. Above 25%: senolytics fail (network bifurcated).

Prediction 3: Redundancy engineering extends lifespan more than single pathways. 4-pathway regeneration > single-pathway enhancement.

Conclusion

Aging is not slow fade. It's a cascade of phase transitions—bifurcation points where biological networks lose coordination and collapse.

Multi-agent safety research revealed: such collapses are sharp, threshold-driven, topology-dependent—and preventable through redundancy engineering.

That's the beach between aging research and AI safety. Both fields are learning: robustness comes from heterogeneity and redundancy, not optimization of single mechanisms.